Telmisartan
From Anvita Health Wiki
Contents |
Introduction
- Tradename: Micardis.
Indications
- treatment of hypertension
Dosage
- Tabs: 20, 40, 80 mg
Pharmacokinetics
- bioavailablity 42-58%, orally active (not prodrug)
- peak effect 0.5-1 hour
- metabolized via conjugation to inactive metabolites
- terminal 1/2life of 24 hours
- 97% excreted in feces
- clearance: 800 mL/min
Adverse-effects
Drug-interactions
- weak inhibitor of cyt P450 2C19
- telmisartain my increase levels of:
- K+ & K+-sparing diuretics may increase risk of hyperkalemia
- warfarin ?
- drug interaction(s) of renin-angiotensin inhibitors with trimethoprim-sulfamethoxazole
- drug interaction(s) of angiotensin II receptor antagonists with aliskiren
- drug interaction(s) of ACE inhibitors with angiotensin II receptor antagonists
- drug interaction(s) of diuretics with angiotensin II receptor antagonists
- drug interaction(s) of NSAIDs with ARBs
- drug interaction(s) of ACE inhibitors, angiotensin II receptor antagonists & beta-blockers
- drug interaction(s) of NSAIDs, diuretics & angiotensin II receptor antagonists
Mechanism-of-action
More General Terms
Internet Database
PubChem: 65999
PubChem: 216293
References
- Kaiser Permanente Northern California Regional Drug Formulary, Update 9/99
- Journal Watch 24(23):174, 2004 Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J; Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004 Nov 4;351(19):1952-61. Epub 2004 Oct 31. PMID: [1]
